Geoff Meacham
Stock Analyst at B of A Securities
(3.58)
# 887
Out of 4,761 analysts
229
Total ratings
52.86%
Success rate
4.56%
Average return
Main Sectors:
Stocks Rated by Geoff Meacham
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $99 → $103 | $68.25 | +50.92% | 3 | Feb 20, 2025 | |
| BIIB Biogen | Maintains: Neutral | $160 → $145 | $140.64 | +3.10% | 14 | Feb 13, 2025 | |
| ABBV AbbVie | Maintains: Buy | $205 → $215 | $202.08 | +6.39% | 16 | Feb 3, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Neutral | $795 → $750 | $700.33 | +7.09% | 20 | Jan 28, 2025 | |
| AMGN Amgen | Maintains: Neutral | $310 → $295 | $303.01 | -2.64% | 11 | Jan 28, 2025 | |
| CRSP CRISPR Therapeutics AG | Maintains: Buy | $98 → $85 | $47.91 | +77.42% | 2 | Jan 7, 2025 | |
| BTAI BioXcel Therapeutics | Downgrades: Underperform | $112 → $4 | $2.13 | +87.79% | 5 | Jan 7, 2025 | |
| NMRA Neumora Therapeutics | Maintains: Buy | $22 → $7 | $1.80 | +288.89% | 2 | Jan 6, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $42 → $45 | $36.85 | +22.12% | 5 | Nov 25, 2024 | |
| GILD Gilead Sciences | Initiates: Buy | $125 | $109.95 | +13.69% | 6 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $575 | $484.24 | +18.74% | 4 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,150 → $1,100 | $873.68 | +25.90% | 9 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $6 → $1 | $0.70 | +42.71% | 3 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $22 → $31 | $13.17 | +135.38% | 2 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $130 → $110 | $35.53 | +209.60% | 9 | Sep 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $10 | $0.39 | +2,473.34% | 2 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $150 → $145 | $89.50 | +62.01% | 6 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $45 | $31.12 | +44.60% | 2 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $80 | $34.55 | +131.55% | 1 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $180 → $170 | $162.30 | +4.74% | 3 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $38 | $33.42 | +13.70% | 2 | Apr 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $48 | $36.01 | +33.30% | 2 | Mar 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $45 → $30 | $36.81 | -18.50% | 3 | Jan 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $68 → $60 | $55.83 | +7.47% | 8 | Jan 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $8 | $1.38 | +479.71% | 2 | Dec 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $23 → $14 | $9.57 | +46.29% | 2 | Sep 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $10 → $8 | $3.30 | +142.42% | 4 | Aug 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $17 | $1.66 | +924.10% | 1 | Aug 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $14 | $1.39 | +907.19% | 3 | Jul 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $50 → $45 | $26.30 | +71.10% | 6 | Apr 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $3.30 | +1,415.15% | 1 | Jan 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $24 | $2.24 | +971.43% | 4 | Nov 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $12 → $4 | $9.18 | -56.43% | 2 | Jun 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $37 → $34 | $20.02 | +69.83% | 2 | Dec 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $1.41 | +1,885.82% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $34 | $0.73 | +4,556.90% | 1 | Jul 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $56 | $5.72 | +879.02% | 3 | May 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $35 | $1.82 | +1,823.08% | 4 | Jan 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $525 | $4.51 | +11,540.80% | 1 | Nov 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $42 | $1.41 | +2,878.72% | 1 | Oct 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $20 | $7.30 | +173.97% | 1 | Sep 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $20 | $1.07 | +1,769.16% | 2 | Sep 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underperform | $9 | $2.91 | +209.81% | 1 | Jun 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $60 | $7.27 | +725.31% | 1 | Jun 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | $7 | $3.83 | +82.77% | 1 | Jun 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $15 → $23 | $14.39 | +59.83% | 3 | Aug 5, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $90 → $82 | $72.11 | +13.72% | 9 | May 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $100 → $95 | $361.10 | -73.69% | 6 | Mar 1, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $300 → $80 | $4.40 | +1,720.25% | 3 | Dec 20, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $43 → $40 | $50.69 | -21.09% | 7 | Nov 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $135 | $120.69 | +11.86% | 2 | Aug 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $15.56 | - | 4 | May 21, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $20 | $1.82 | +1,001.93% | 4 | May 3, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | n/a | $36.91 | - | 2 | Apr 5, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $127 → $158 | $250.59 | -36.95% | 5 | Nov 8, 2017 |
BioMarin Pharmaceutical
Feb 20, 2025
Maintains: Buy
Price Target: $99 → $103
Current: $68.25
Upside: +50.92%
Biogen
Feb 13, 2025
Maintains: Neutral
Price Target: $160 → $145
Current: $140.64
Upside: +3.10%
AbbVie
Feb 3, 2025
Maintains: Buy
Price Target: $205 → $215
Current: $202.08
Upside: +6.39%
Regeneron Pharmaceuticals
Jan 28, 2025
Maintains: Neutral
Price Target: $795 → $750
Current: $700.33
Upside: +7.09%
Amgen
Jan 28, 2025
Maintains: Neutral
Price Target: $310 → $295
Current: $303.01
Upside: -2.64%
CRISPR Therapeutics AG
Jan 7, 2025
Maintains: Buy
Price Target: $98 → $85
Current: $47.91
Upside: +77.42%
BioXcel Therapeutics
Jan 7, 2025
Downgrades: Underperform
Price Target: $112 → $4
Current: $2.13
Upside: +87.79%
Neumora Therapeutics
Jan 6, 2025
Maintains: Buy
Price Target: $22 → $7
Current: $1.80
Upside: +288.89%
BridgeBio Pharma
Nov 25, 2024
Maintains: Buy
Price Target: $42 → $45
Current: $36.85
Upside: +22.12%
Gilead Sciences
Nov 14, 2024
Initiates: Buy
Price Target: $125
Current: $109.95
Upside: +13.69%
Nov 14, 2024
Initiates: Buy
Price Target: $575
Current: $484.24
Upside: +18.74%
Oct 31, 2024
Maintains: Buy
Price Target: $1,150 → $1,100
Current: $873.68
Upside: +25.90%
Oct 30, 2024
Downgrades: Underperform
Price Target: $6 → $1
Current: $0.70
Upside: +42.71%
Oct 18, 2024
Upgrades: Buy
Price Target: $22 → $31
Current: $13.17
Upside: +135.38%
Sep 13, 2024
Maintains: Neutral
Price Target: $130 → $110
Current: $35.53
Upside: +209.60%
Aug 19, 2024
Maintains: Buy
Price Target: $12 → $10
Current: $0.39
Upside: +2,473.34%
Jul 31, 2024
Maintains: Buy
Price Target: $150 → $145
Current: $89.50
Upside: +62.01%
Jun 13, 2024
Maintains: Buy
Price Target: $40 → $45
Current: $31.12
Upside: +44.60%
May 10, 2024
Initiates: Buy
Price Target: $80
Current: $34.55
Upside: +131.55%
Apr 17, 2024
Maintains: Neutral
Price Target: $180 → $170
Current: $162.30
Upside: +4.74%
Apr 12, 2024
Maintains: Buy
Price Target: $40 → $38
Current: $33.42
Upside: +13.70%
Mar 13, 2024
Maintains: Buy
Price Target: $24 → $48
Current: $36.01
Upside: +33.30%
Jan 3, 2024
Downgrades: Neutral
Price Target: $45 → $30
Current: $36.81
Upside: -18.50%
Jan 3, 2024
Downgrades: Neutral
Price Target: $68 → $60
Current: $55.83
Upside: +7.47%
Dec 15, 2023
Downgrades: Neutral
Price Target: $8
Current: $1.38
Upside: +479.71%
Sep 8, 2023
Downgrades: Neutral
Price Target: $23 → $14
Current: $9.57
Upside: +46.29%
Aug 21, 2023
Maintains: Underperform
Price Target: $10 → $8
Current: $3.30
Upside: +142.42%
Aug 21, 2023
Maintains: Buy
Price Target: $19 → $17
Current: $1.66
Upside: +924.10%
Jul 20, 2023
Reinstates: Buy
Price Target: $14
Current: $1.39
Upside: +907.19%
Apr 21, 2023
Maintains: Neutral
Price Target: $50 → $45
Current: $26.30
Upside: +71.10%
Jan 5, 2023
Initiates: Buy
Price Target: $50
Current: $3.30
Upside: +1,415.15%
Nov 1, 2022
Downgrades: Underperform
Price Target: $24
Current: $2.24
Upside: +971.43%
Jun 8, 2022
Downgrades: Neutral
Price Target: $12 → $4
Current: $9.18
Upside: -56.43%
Dec 29, 2021
Maintains: Buy
Price Target: $37 → $34
Current: $20.02
Upside: +69.83%
Aug 10, 2021
Initiates: Buy
Price Target: $28
Current: $1.41
Upside: +1,885.82%
Jul 13, 2021
Initiates: Buy
Price Target: $34
Current: $0.73
Upside: +4,556.90%
May 7, 2021
Upgrades: Buy
Price Target: $56
Current: $5.72
Upside: +879.02%
Jan 15, 2021
Downgrades: Neutral
Price Target: $35
Current: $1.82
Upside: +1,823.08%
Nov 23, 2020
Initiates: Buy
Price Target: $525
Current: $4.51
Upside: +11,540.80%
Oct 20, 2020
Initiates: Buy
Price Target: $42
Current: $1.41
Upside: +2,878.72%
Sep 15, 2020
Reinstates: Buy
Price Target: $20
Current: $7.30
Upside: +173.97%
Sep 8, 2020
Reinstates: Buy
Price Target: $20
Current: $1.07
Upside: +1,769.16%
Jun 25, 2020
Reinstates: Underperform
Price Target: $9
Current: $2.91
Upside: +209.81%
Jun 25, 2020
Reinstates: Buy
Price Target: $60
Current: $7.27
Upside: +725.31%
Jun 25, 2020
Initiates: Underperform
Price Target: $7
Current: $3.83
Upside: +82.77%
Aug 5, 2019
Maintains: Equal-Weight
Price Target: $15 → $23
Current: $14.39
Upside: +59.83%
May 3, 2019
Downgrades: Equal-Weight
Price Target: $90 → $82
Current: $72.11
Upside: +13.72%
Mar 1, 2019
Maintains: Underweight
Price Target: $100 → $95
Current: $361.10
Upside: -73.69%
Dec 20, 2018
Downgrades: Equal-Weight
Price Target: $300 → $80
Current: $4.40
Upside: +1,720.25%
Nov 6, 2018
Maintains: Equal-Weight
Price Target: $43 → $40
Current: $50.69
Upside: -21.09%
Aug 1, 2018
Maintains: Overweight
Price Target: $100 → $135
Current: $120.69
Upside: +11.86%
May 21, 2018
Downgrades: Underweight
Price Target: n/a
Current: $15.56
Upside: -
May 3, 2018
Maintains: Equal-Weight
Price Target: $16 → $20
Current: $1.82
Upside: +1,001.93%
Apr 5, 2018
Downgrades: Equal-Weight
Price Target: n/a
Current: $36.91
Upside: -
Nov 8, 2017
Maintains: Overweight
Price Target: $127 → $158
Current: $250.59
Upside: -36.95%